Telmisartan and Rosuvastatin Tablets 80/20 mg
Telmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
IlYang Biopharm Co., Ltd.
MFDS item code 202101821 · Approved 2021.02.24
This product's status changed to Expired on 2026.02.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension and dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression
This medication is used for patients who require concomitant administration of the two components, telmisartan and rosuvastatin. Telmisartan is primarily used to reduce the risk of myocardial infarction, stroke, and death from cardiovascular disease in patients with essential hypertension and those over 55 years old who are at high risk for cardiovascular disease. Rosuvastatin helps lower cholesterol levels in patients with hypercholesterolemia and mixed dyslipidemia, and primary dysbetalipoproteinemia, in conjunction with dietary therapy, while delaying the progression of atherosclerosis. Additionally, it helps reduce the risk of stroke and myocardial infarction in middle-aged and older patients with cardiovascular risk factors. This medication is used to protect cardiovascular health and reduce the risk of related diseases.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg once daily by mouth as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg once daily by mouth. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Women of childbearing potential must use appropriate contraception before taking this medication, and it should not be taken during pregnancy or while breastfeeding. Patients with severely impaired liver or kidney function, certain liver diseases or muscle disorders, and those allergic to this medication or its components should not take it. Elderly patients or those with high blood potassium levels or mildly impaired liver function should use this medication with caution, requiring regular blood tests and monitoring of health status. Muscle-related side effects such as muscle pain or weakness can occur with this medication; if these symptoms arise, consult a doctor immediately. Additionally, this medication may affect liver function; therefore, liver function tests should be performed periodically before and during treatment. This medication may interact with other drugs; inform your doctor or pharmacist of any other medications you are taking, especially blood pressure medications, diuretics, potassium supplements, certain antibiotics, and antifungals. Overdosage may result in hypotension, dizziness, and decreased kidney function, necessitating immediate contact with a medical facility for appropriate treatment. Dizziness or drowsiness may occur during driving or operating machinery while taking this medication, so caution is advised. Finally, it is not recommended for children as safety and efficacy have not been established.
Increased ALT, increased AST, increased serum creatine phosphokinase (CPK), dizziness, itching, indigestion, oral paresthesia, musculoskeletal stiffness, acne, nasopharyngitis, increased serum potassium, glycosuria, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasms, hemorrhoids, skeletal pain, osteoporosis, sensory loss, dyskinesia, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disorders, increased sweating, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, headache, facial spasm, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, fatigue, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, hypersensitivity reactions including angioedema, diabetes, headache, constipation, nausea, pancreatitis, itching, rash, urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, interstitial lung disease, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, headache, cough, palpitations, fatigue, nausea, insufficient effect, myalgia, joint pain, increased CK, constipation, numbness, sensory disturbances, chest discomfort, abdominal pain, diarrhea, loss of appetite, abdominal distension, syncope, systemic pain, muscle cramps, gout, erectile dysfunction, acute kidney failure, oliguria, thrombocytopenia, increased serum creatinine
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This ensures that the medication's efficacy and safety are preserved over time.
Pale pink oval film-coated tablets
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
IlYang Biopharm Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.